__NUXT_JSONP__("/drugs/Blinatumomab", (function(a,b,c,d,e){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy (see section 4.2).",inn:b,marketingAuthorisationDate:"2015-11-23 01:00:00",marketingAuthorisationHolder:"Amgen Europe B.V.",medicineName:c,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fblincyto"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"853426-35-4",chebiId:d,chemicalFormula:d,definition:"A recombinant, single-chain, anti-CD19\u002Fanti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.",fdaUniiCode:"4FR53SIF3A",identifier:"C62528",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C1454"],synonyms:["Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody","Anti-CD19\u002FAnti-CD3 Recombinant Bispecific Monoclonal Antibody MT103","BLINATUMOMAB",a,c,"MEDI-538","MT-103"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FBlinatumomab",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("Blinatumomab","blinatumomab","Blincyto","","2021-10-30T13:42:12.443Z")));